Australia's most trusted
source of pharma news
Saturday, 10 May 2025
Posted 8 December 2023 AM
Heart and stroke warnings for Amgen's bone drug Evenity have been toughened following a TGA investigation of safety signals, including two Aussie deaths.
The investigation, undertaken by the regulator's Pharmacovigilance Branch in October, looked at local adverse event reports and two pivotal studies published in the New England Journal of Medicine.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.